10-Q: Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

Viridian Therapeutics reports a net loss of $76.7 million for the third quarter of 2024, while highlighting progress in its clinical programs for thyroid eye disease and FcRn inhibitors.

Summary

• Viridian Therapeutics reported a net loss of $76.7 million for the three months ended September 30, 2024, compared to a net loss of $47.7 million for the same period in 2023.
• The company's research and development expenses increased significantly to $69.2 million in the third quarter of 2024, up from $30.4 million in the same quarter of the previous year.
• General and administrative expenses decreased to $14.4 million in the third quarter of 2024, compared to $20.9 million in the third quarter of 2023.
• As of September 30, 2024, Viridian had approximately $753.2 million in cash, cash equivalents, and short-term investments.
• The company expects its current resources to fund operations into the second half of 2027.
• Viridian announced positive topline data from its THRIVE trial for veligrotug in active thyroid eye disease.
• The company initiated two global phase 3 clinical trials for VRDN-003 in active and chronic thyroid eye disease in August 2024.
• Viridian plans to file an IND for VRDN-006 by the end of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and a strong cash position, the significant net loss and increased R&D expenses raise concerns. The company's future success is heavily dependent on clinical trial outcomes and regulatory approvals, which are inherently risky.

Positives

• The company has a strong cash position of $753.2 million, which is expected to fund operations into the second half of 2027.
• Positive topline data from the THRIVE trial for veligrotug was achieved.
• The interest-only period for the Hercules Loan was extended, providing additional financial flexibility.
• The company is actively advancing its pipeline with the initiation of two phase 3 trials for VRDN-003 and plans to file an IND for VRDN-006.
• The company has access to additional undrawn funds under the Hercules Amended Term Loan.

Negatives

• The company reported a significant net loss of $76.7 million for the third quarter of 2024.
• Research and development expenses increased substantially to $69.2 million in the third quarter of 2024.
• The company has a history of incurring losses and expects to continue to incur significant losses for the foreseeable future.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.

Risks

• The company's ability to secure additional capital is dependent on various factors, including success in developing product candidates and market conditions.
• Failure to raise capital as needed could negatively impact the company's financial condition and ability to develop product candidates.
• Clinical trials are costly, time-consuming, and inherently risky, and the company may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The company is heavily dependent on the success of its product candidates, which are in clinical development.
• The company relies on third parties to conduct preclinical development activities, clinical trials, and manufacture product candidates, and failure of these third parties to perform successfully could harm the business.
• The company faces substantial competition and competitors may discover, develop, or commercialize products faster or more successfully.
• The company's future success depends on its ability to attract, retain, and motivate qualified personnel.

Future Outlook

The company expects its current resources to fund operations into the second half of 2027 and anticipates filing a BLA for veligrotug in the second half of 2025 and a BLA for VRDN-003 by the end of 2026.

Management Comments

• The company is focused on advancing its clinical programs for thyroid eye disease and FcRn inhibitors.
• The company believes VRDN-003 has the potential to be the best-in-class subcutaneous anti-IGF-1R product candidate.
• The company is engineering product candidates to address unmet medical needs for patients and further advance drug innovation.

Industry Context

The company is developing therapies for thyroid eye disease, a rare autoimmune disease, and is also developing a portfolio of anti-FcRn inhibitors, which have the potential to treat a broad array of autoimmune diseases. The company is competing with other pharmaceutical and biotechnology companies in these areas.

Comparison to Industry Standards

• Viridian is developing veligrotug, an IGF-1R inhibitor, which is a clinically validated target for thyroid eye disease, similar to Horizon Therapeutics' Tepezza.
• Viridian's VRDN-003 is designed to be a subcutaneous version of an IGF-1R inhibitor, aiming to improve convenience compared to intravenous treatments like Tepezza.
• The company is also developing anti-FcRn inhibitors, a class of drugs that is being pursued by other companies like argenx and Immunovant.
• Viridian's approach to engineering FcRn inhibitors aims to address limitations of current agents, such as incomplete IgG suppression and dosing inconvenience, which is a common goal in the industry.
• The company's focus on fast-follower therapeutics that improve on existing treatments is a common strategy in the biopharmaceutical industry.

Related Party Transactions

• The Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC beneficially owns more than 5% of the company's common stock and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma's board of directors.
• The Paragon Agreements are considered related party transactions because Fairmount beneficially owns more than 5% of the company's capital stock and has two seats on the company's board of directors, and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon's board of directors and has the contractual right to approve the appointment of any executive officers.

Stakeholder Impact

• Shareholders may be concerned about the increasing net losses and the need for additional capital.
• Employees may be affected by the company's financial performance and any potential restructuring or layoffs.
• Patients may benefit from the company's development of new therapies for thyroid eye disease and other autoimmune diseases.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• The company expects to announce topline data for the THRIVE-2 study by the end of 2024.
• The company anticipates filing a BLA for veligrotug in the second half of 2025.
• The company anticipates topline data for REVEAL-1 and REVEAL-2 in the first half of 2026.
• The company anticipates submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.
• The company plans to file an IND for VRDN-006 by the end of 2024.
• The company expects healthy volunteer data for VRDN-006 in the second half of 2025.

Key Dates

Keywords

Thyroid Eye Disease, TED, Veligrotug, VRDN-003, VRDN-006, FcRn Inhibitors, Clinical Trials, Biopharmaceutical, Monoclonal Antibody, Regulatory Approval